Pharmaceutical - Pharmaceutical, Bristol-Myers Squibb

Filter

Popular Filters

1 to 25 of 215 results

Global melanoma market set to reach $3.6 billion by 2020

12-11-2014

The global melanoma therapeutics market was valued at $1.3 billion in 2013 and will expand at a compound…

Bristol-Myers SquibbEuropeJapanKeytrudaMarkets & MarketingMerck & CoOncologyOpdivoPharmaceuticalUSAYervoy

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

10-11-2014

The Scottish Medicines Consortium has approved two new treatments today, one for skin cancer and one…

Bristol-Myers SquibbDaklinzaNephrology and HepatologyOncologyPharmaceuticalRegulationUKYervoy

Bristol-Myers reveals access plan for hep C drug daclatasvir

03-11-2014

US Pharma major Bristol-Myers Squibb has recently revealed a commercial strategy for sales of its new…

Anti-viralsBristol-Myers SquibbdaclatasvirDaklinzaMarkets & MarketingPharmaceuticalPricing

Bristol-Myers Squibb signs deal with Korean company OliPass

Bristol-Myers Squibb signs deal with Korean company OliPass

28-10-2014

Privately-held Korean biopharmaceutical company OliPass has announced a worldwide strategic alliance…

Bristol-Myers SquibbOliPassPharmaceuticalResearchRest of the World

Bristol-Myers Squibb third-qtr earnings top expectations

Bristol-Myers Squibb third-qtr earnings top expectations

25-10-2014

US pharma major Bristol-Myers Squib posted a strong set of financials for the third quarter of 2014,…

Bristol-Myers SquibbFinancialPharmaceutical

Most-used agents in US bipolar disorder treatment sector; report

Most-used agents in US bipolar disorder treatment sector; report

24-10-2014

Through analysis of US longitudinal patient-level claims data, Bristol-Myers Squibb and Otsuka’s Abilify…

AbilifyBristol-Myers SquibbCymbaltaDainippon Sumitomo PharmaEli LillyGlaxoSmithKlineLamotrigineLatudaMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Bristol-Myers resolves Sustiva patent litigation in USA

Bristol-Myers resolves Sustiva patent litigation in USA

08-10-2014

US pharma major Bristol-Myers Squibb has successfully resolved all outstanding US patent litigation relating…

Anti-viralsAtriplaBristol-Myers SquibbCiplaLegalMerck & CoPatentsPharmaceuticalSustivaUSA

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

08-10-2014

Bristol-Myers Squibb has decided that it will not pursue US Food and Drug Administration approval of…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirGenotypeGilead SciencesMarkets & MarketingPharmaceuticalRegulationSovaldiUnited StatesUS Food and Drug AdministrationUSA

Novartis and Bristol-Myers Squibb sign NSCLC collaboration

Novartis and Bristol-Myers Squibb sign NSCLC collaboration

07-10-2014

Swiss drug major Novartis and US peer Bristol-Myers Squibb have announced a clinical collaboration to…

Bristol-Myers SquibbNovartisOncologyOpdivoPharmaceuticalResearchUSAZykadia

Satish Jindal appointed to lead drug discovery at Allied-Bristol Life Sciences

Satish Jindal appointed to lead drug discovery at Allied-Bristol Life Sciences

06-10-2014

Satish Jindal has been appointed to lead the discovery of drug candidates from leading academic institutions…

Allied MindsBoardroomBristol-Myers SquibbPharmaceuticalUSA

Positive results with Portola’s anti-clotting agent andexanet alfa and Eliquis

Positive results with Portola’s anti-clotting agent andexanet alfa and Eliquis

01-10-2014

Portola Pharmaceuticals says that its first Phase III study of andexanet alfa, a potential universal…

andexanet alfaBayerBristol-Myers SquibbCardio-vascularedoxabanEliquisJanssenPfizerPharmaceuticalPortola PharmaceuticalsRegulationResearchUSAXarelto

Bristol-Myers Squibb updates on Opdivo regulatory milestones

Bristol-Myers Squibb updates on Opdivo regulatory milestones

30-09-2014

US pharma major Bristol-Myers Squibb has announced multiple regulatory milestones for Opdivo (nivolumab),…

Bristol-Myers SquibbEuropeOncologyOno PharmaceuticalOpdivoPharmaceuticalRegulationUSA

Bristol-Myers Squibb and Ono Pharma sue Merck over Keytruda

Bristol-Myers Squibb and Ono Pharma sue Merck over Keytruda

08-09-2014

US drug major Bristol-Myers Squibb and partner Japan’s Ono Pharmaceutical have filed a law suit against…

Advanced melanomaBristol-Myers SquibbIpilimumabKeytrudaLaw suitLegalMerck & CoOncologyOno PharmaceuticalPharmaceuticalUSA

Bristol-Myers Squibb launches Daklinza in the UK for chronic hepatitis C

Bristol-Myers Squibb launches Daklinza in the UK for chronic hepatitis C

03-09-2014

US drug major Bristol-Myers Squibb has launched Daklinza (daclastavir) in the UK for chronic hepatitis…

AntiviralsBristol-Myers SquibbDaklinzaHepatitis CNephrology and HepatologyPharmaceuticalRegulationUK

Bristol-Myers’ hep C drug Daklinza approved in Europe

Bristol-Myers’ hep C drug Daklinza approved in Europe

27-08-2014

US pharma major Bristol-Myers Squibb says that the European Commission has approved Daklinza (daclatasvir),…

Anti-viralsBristol-Myers SquibbDaklinzaEuropeGilead SciencesPharmaceuticalRegulationSovaldi

Indian Health Ministry seeking compulsory license for B-MS’ Sprycel

Indian Health Ministry seeking compulsory license for B-MS’ Sprycel

19-08-2014

Anti-leukemia drug dasatinib, made by US pharma major Bristol-Myers Squibb and sold in India under the…

Bristol-Myers SquibbDasatinibIndiaOncologyPatentsPharmaceuticalSprycel

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

30-07-2014

The European Commission has approved US pharma majors Bristol-Myers Squibb and Pfizer’s Eliquis (apixaban)…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

New study identifies potential alternatives to Gilead’s Sovaldi

New study identifies potential alternatives to Gilead’s Sovaldi

29-07-2014

There are multiple hepatitis treatments in development that may serve as potential alternatives to Gilead…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbdaclatasvirGilead SciencesGlobalHepatitis C treatmentMarkets & MarketingmericitabinePharmaceuticalRocheSovaldi

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

Bristol-Myers and Ono Pharma enter Asia oncology accord

Bristol-Myers and Ono Pharma enter Asia oncology accord

24-07-2014

US pharma major Bristol-Myers Squibb and Japan’s Ono Pharmaceutical have signed a strategic collaboration…

Asia-PacificBristol-Myers SquibbJapanLicensinglirilumabMelanomaOncologyOno PharmaceuticalOpdivoPharmaceuticalurelumabYervoy

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

23-07-2014

The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending…

Astellas PharmaBristol-Myers SquibbOncologyPharmaceuticalRegulationUKXtandiYervoy

Bristol-Myers to file Opdivo BLA earlier than expected

Bristol-Myers to file Opdivo BLA earlier than expected

10-07-2014

Following discussions with the US Food and Drug Administration, Bristol-Myers Squibb is planning a third…

Bristol-Myers SquibbnivolumabOncologyOpdivoPharmaceuticalRegulationUSA

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

07-07-2014

The Japanese Ministry of Health, Labor and Welfare has approved Daklinza (daclatasvir), a potent, pan-genotypic…

Anti-viralsBristol-Myers SquibbDaklinzaDaklinza+SunvepraJapanPharmaceuticalRegulationSunvepra

1 to 25 of 215 results

Back to top